| [1] |
Bedell C. Pegfilgrastim for chemotherapy-induced neutropenia[J].Clin J Oncol Nurs, 2003, 7(1):55-56.
|
| [2] |
Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage Ⅱ or stage Ⅲ/Ⅳ breast cancer[J]. J Clin Oncol, 2002, 20(3):727-731.
|
| [3] |
Hebert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions[J]. JAMA, 2003, 289(15):1941-1949.
|
| [4] |
Blajchman MA. Immunomodulation and blood transfusion[J]. Am J Ther, 2002, 9(5):389-395.
|
| [5] |
Maekawa K. Overview of medical care for highly exposed victims in the Tokaimura accident[A]. Ricks RC, Berger ME, O'Hara FM, eds.The Medical Basis for Radiation Accident Preparedness:The Clinical Care of Victims[C]. New York:Parthenon, 2002.313-318.
|
| [6] |
Fliedner TM, Graessle D, Reimers K, et al. Stem cell transplantation in radiation accidents[A]. Medical Aspects of Radiation Emergency:The Criticality Accident in Tokaimura. Chiba[C]. Japan:National Institute of Radiological Sciences, 2000. 228-235.
|
| [7] |
Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer[J].Clin Infect Dis, 2002, 34(6):730-751.
|
| [8] |
Hughes WT. Use of antimicrobial agents for treatment of infection in the neutropenic immunocompromised patient[A]. Ricks RC, Berger ME, O'Hara FM, et al. The Medical Basis for Radiation-Accident Preparedness. The Clinical Care of Victims[C]. Washington DC:Parthenon, 2002. 117-129.
|
| [9] |
Brook I, Elliott TB, Ledney GD, et al. Management of postirradiation sepsis[J]. Mil Med, 2002, 167(2 suppl):105-106.
|
| [10] |
National council on Radiation Protection and Measurements.Management of Terrorist Events Involving Radioactive Material.NCRP Report No. 138[C]. Bethesda, MD, 2001. 125-134.
|
| [11] |
U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance:Potassium iodide as a thyroid blocking agent in radiation emergencies. December 2001. www.fda.gov/cder/guidance/4825fnl.pdf.
|